HC Wainwright Reiterates “Buy” Rating for Actinium Pharmaceuticals (NYSE:ATNM)

Actinium Pharmaceuticals (NYSE:ATNM)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a report released on Tuesday,Benzinga reports. They currently have a $4.00 price objective on the stock. HC Wainwright’s price objective points to a potential upside of 163.16% from the stock’s current price. HC Wainwright also issued estimates for Actinium Pharmaceuticals’ Q1 2025 earnings at ($0.26) EPS, Q2 2025 earnings at ($0.30) EPS, Q3 2025 earnings at ($0.35) EPS and Q4 2025 earnings at ($0.39) EPS.

Actinium Pharmaceuticals Price Performance

Shares of ATNM stock opened at $1.52 on Tuesday. The business’s 50 day simple moving average is $1.27 and its 200 day simple moving average is $1.44. Actinium Pharmaceuticals has a one year low of $1.03 and a one year high of $10.24. The stock has a market capitalization of $47.42 million, a PE ratio of -1.09 and a beta of 0.10.

Institutional Investors Weigh In On Actinium Pharmaceuticals

Institutional investors have recently modified their holdings of the company. Vontobel Holding Ltd. acquired a new position in Actinium Pharmaceuticals in the fourth quarter valued at $32,000. Sei Investments Co. acquired a new position in shares of Actinium Pharmaceuticals in the 4th quarter valued at about $62,000. Barclays PLC lifted its stake in shares of Actinium Pharmaceuticals by 323.0% in the 3rd quarter. Barclays PLC now owns 42,935 shares of the company’s stock valued at $81,000 after purchasing an additional 32,784 shares during the period. Bank of America Corp DE boosted its position in shares of Actinium Pharmaceuticals by 76.6% during the 4th quarter. Bank of America Corp DE now owns 78,767 shares of the company’s stock valued at $99,000 after purchasing an additional 34,176 shares in the last quarter. Finally, Wellington Management Group LLP bought a new stake in Actinium Pharmaceuticals in the third quarter worth approximately $112,000. 27.50% of the stock is owned by institutional investors.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).